Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?

Research output: Contribution to journalReview articlepeer-review

Original languageEnglish
Pages (from-to)2599-2617
Number of pages19
JournalTranslational Lung Cancer Research
Volume9
Issue number6
DOIs
Publication statusPublished - Dec 2020

Keywords

  • Non-small cell lung cancer (NSCLC)
  • central nervous system metastases (CNS metastases)
  • oligometastatic disease
  • tyrosine kinase inhibitors (TKIs)
  • DABRAFENIB PLUS TRAMETINIB
  • POSITIVE SOLID TUMORS
  • EML4-ALK FUSION GENE
  • HIGH-DOSE ERLOTINIB
  • BRAIN METASTASES
  • OPEN-LABEL
  • EGFR-MUTATION
  • LEPTOMENINGEAL METASTASES
  • CEREBROSPINAL-FLUID
  • 1ST-LINE TREATMENT

Cite this